HCWB
HCW Biologics Inc (HCWB)
Healthcare • NASDAQ • $1.11+2.78%
- Symbol
- HCWB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.11
- Daily Change
- +2.78%
- Market Cap
- $7.81M
- Trailing P/E
- N/A
- Forward P/E
- -1.98
- 52W High
- $7.35
- 52W Low
- $0.25
- Analyst Target
- $5.00
- Dividend Yield
- N/A
- Beta
- 2.21
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-…
Company websiteResearch HCWB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.